Goldman Sachs
FOLD

Goldman Sachs’s Amicus Therapeutics FOLD Stock Holding History

Goldman Sachs’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-160,000
Closed -$1.85M – 6668
2021
Q4 		$1.85M Buy
+160,000
New +$1.78M ﹤0.01% 4317
2021
Q2 		– Sell
-370,000
Closed -$3.66M – 6305
2021
Q1 		$3.66M Buy
370,000
+297,700
+412% +$4.61M ﹤0.01% 3431
2020
Q4 		$1.67M Buy
+72,300
New +$1.48M ﹤0.01% 3852
2018
Q1 		– Sell
-300,000
Closed -$4.32M – 6052
2017
Q4 		$4.32M Buy
300,000
+400
+0.1% +$5.5K ﹤0.01% 3136
2017
Q3 		$4.52M Buy
299,600
+259,600
+649% +$3.43M ﹤0.01% 3249
2017
Q2 		$403K Buy
+40,000
New +$322K ﹤0.01% 5270
2016
Q3 		– Sell
-46,800
Closed -$256K – 7066
2016
Q2 		$256K Sell
46,800
-23,600
-34% -$165K ﹤0.01% 5479
2016
Q1 		$595K Buy
70,400
+39,600
+129% +$280K ﹤0.01% 4578
2015
Q4 		$299K Buy
+30,800
New +$278K ﹤0.01% 5353
2015
Q2 		– Sell
-23,600
Closed -$257K – 7312
2015
Q1 		$257K Buy
+23,600
New +$208K ﹤0.01% 5787
2013
Q4 		– Sell
-29,500
Closed -$68K – 6693
2013
Q3 		$68K Hold
29,500
– – ﹤0.01% 6253
2013
Q2 		$69K Buy
+29,500
New +$90.7K ﹤0.01% 5979

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Goldman Sachs's FOLD Position: Q1 2026 in Review

Goldman Sachs increased its Amicus Therapeutics (FOLD) stake by 88% in Q1 2026, buying an estimated $77.6M and bringing the position to 11,556,008 shares worth $167M. The position accounts for 0.02% of the portfolio, ranked #762.

Goldman Sachs first reported a position in FOLD in Q2 2013 and has held it in 52 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Goldman Sachs held 11,556,008 shares of Amicus Therapeutics worth $167M as of Q1 2026.
  • Goldman Sachs bought 5,413,052 Amicus Therapeutics shares in Q1 2026, an estimated $77.6M.
  • Amicus Therapeutics made up 0.02% of Goldman Sachs's portfolio in Q1 2026, its #762 holding.
  • Goldman Sachs first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.